Market closed

Chimerix/$CMRX

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Chimerix

Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.

Ticker

$CMRX
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Durham, United States

Employees

72
Website
www.chimerix.com

Chimerix Metrics

BasicAdvanced
$298M
-
-$0.94
1.13
-

$298M

1.13

$3.80

$0.75

8.3M

6.334

6.131

0.474

0.474

-30.22%

-48.59%

1,861.642

2.19

2.19

-4.201

-85.98%

-2.37%

-62.66%

-20.19%

What the Analysts think about Chimerix

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Chimerix stock.

Chimerix Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Chimerix Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Chimerix News

AllArticlesVideos
Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma

Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma

GlobeNewsWire·2 weeks ago
Chimerix: Big News, Big Moves, So Maybe Now's The Time To Buy

Chimerix: Big News, Big Moves, So Maybe Now's The Time To Buy

Seeking Alpha·1 month ago
Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End

Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End

GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CMRX

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Chimerix stock?

Chimerix (CMRX) has a market cap of $298M as of January 15, 2025.

What is the P/E ratio for Chimerix stock?

The price to earnings (P/E) ratio for Chimerix (CMRX) stock is 0 as of January 15, 2025.

Does Chimerix stock pay dividends?

No, Chimerix (CMRX) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Chimerix dividend payment date?

Chimerix (CMRX) stock does not pay dividends to its shareholders.

What is the beta indicator for Chimerix?

Chimerix (CMRX) has a beta rating of 1.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.